 |
 Video: What is a Stock Split?
|
|
|
| Morphic is a biopharmaceutical company. Co. is applying its proprietary insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with various approved injectable blockbuster drugs for the treatment of chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. Co. is developing its pipeline, including its main product candidate, MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease. Co. has also developed selective oral avß6-specific integrin inhibitors including MORF-720 and MORF-627. According to our Morphic Holding stock split history records, Morphic Holding has had 0 splits. | |
|
Morphic Holding (MORF) has 0 splits in our Morphic Holding stock split history database.
Looking at the Morphic Holding stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Morphic Holding shares, starting with a $10,000 purchase of MORF, presented on a split-history-adjusted basis factoring in the complete Morphic Holding stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/28/2019 |
|
| End date: |
05/03/2024 |
|
| Start price/share: |
$19.82 |
|
| End price/share: |
$29.90 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
50.86% |
|
| Average Annual Total Return: |
8.84% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$15,083.43 |
|
| Years: |
4.85 |
|
|
|
|
|
